PreveCeutical Medical Inc. PRVCF Archives - Page 5 of 6

MondayMay 07, 2018 10:37 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Inks NDA with Global Drug Delivery Device Manufacturer

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that it has signed a non-disclosure agreement ("NDA") with an internationally known drug delivery device manufacturer. The NDA permits PreveCeutical to have discussions with the manufacturer regarding the supply of spray devices for use in the company's soluble gel ("Sol‑gel") drug delivery research program. The company’s research partner, the University of Queensland, has received various prototype spray devices from the manufacturer at the Pharmacy Australia Centre of Excellence, where testing of the devices for the program is taking place. "We are pleased to have signed an…

ThursdayMay 03, 2018 11:50 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Obtains Additional Permits from Australian Government for Cannabis Importation

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that it has been granted two additional permits by the Australian Government, Department of Health, for the importation of a second shipment of cannabis plant materials for research purposes and the shipment of dried cannabis materials in accordance with the permits. The permits, which have been granted to the Pharmacy Australia Centre of Excellence (“PACE”) at the University of Queensland, enable PACE to import cannabis plant material shipments for research purposes. The company’s Canadian licensed producer partner also obtained the mandatory Canadian permits to export their…

MondayApr 16, 2018 12:05 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Conducts Cannabinoid-based Sol-gel Product Research at University of Queensland

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) recently announced the grant of three permits from the Australian government’s Department of Health that enable the importation of cannabis into Australia. The permits, which have been granted to the Pharmacy Australia Centre of Excellence (“PACE”) at the University of Queensland, will allow PACE to import cannabis plant material shipments for research purposes. An article discussing the company reads: “The intention of PreveCeutical is to apply its Sol-gel technology to cannabinoids for the development of therapies to relieve a variety of symptoms, including pain, inflammation, seizures and neurological disorders.…

MondayApr 09, 2018 1:00 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Schedules 2018 Annual Meeting; Announces Non-Brokered Private Placement

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced a non-brokered private placement of up to 16 million units at the price of $0.25 per unit for total gross proceeds of up to CAD$4,000,000. Each unit is comprised of one common share of the company and one warrant with an exercise price of $0.50 per share for a period of 24 months from the closing of the offering. The units are subject to an acceleration provision that enables sooner expiration of the warrants if the closing price of the shares on the Canadian Securities Exchange…

ThursdayApr 05, 2018 10:12 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Continues to Advance Sol-gel Drug Delivery Technology

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) believes that its unique cannabinoid-based, nose-to-brain delivery technology, which employs its Sol-gel platform, is on track to become the first of its kind to be FDA-approved. An article discussing the company’s technology reads: “PreveCeutical believes that its cannabinoid-based nose-to-brain delivery technology, using a Sol-gel platform, will be the first to gain Food and Drug Administration approval. Its water soluable, alcohol free nasal formulation which will be developed for use by adults, children and people of certain beliefs. … PreveCeutical’s groundbreaking Sol-gel delivery system displays significant benefits over other contemporary…

ThursdayMar 29, 2018 10:08 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Announces Arrival of First Cannabis Shipment at University of Queensland

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the arrival of the first shipment of dried cannabis flower and oils from Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) at the University of Queensland’s Pharmacy Australia Centre of Excellence. Per the news release, testing of the imported cannabis strains in the application of PreveCeutical’s Sol-gel drug delivery technology is now expected to commence. The impending Sol-gel program aims to develop a system that will increase the bioavailability of drugs through the use of an innovative nose-to-brain delivery platform. The company notes that Sol-gels could…

TuesdayFeb 27, 2018 4:33 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) CEO, Chief Research Officer Discuss Company’s Response to Opioid Epidemic

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was featured in an interview today by Proactive Investors. Chairman and CEO Stephen Van Deventer and chief research officer Dr. Harry Parekh discussed the company’s four programs: Sol-Gel, Nature Identical™, Dual Gene Therapy and Engineering Peptide Therapeutics. Among other topics, they discuss the rising rate of opioid overdoses and addiction, which the company’s planning to tackle utilizing its proprietary linker technology to engineer peptide therapeutics. “What's key about the technology is you cannot create tolerance to this treatment and you cannot overdose as well,” PreveCeutical chairman and CEO…

MondayFeb 26, 2018 11:17 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Appoints Director of International Operations

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its appointment of Dr. Maher Khaled to the position of director of international operations. Khaled bolsters the PreveCeutical team with more than a decade of experience in commercializing therapeutic and diagnostic technologies, most recently at UniQuest Pty Ltd. Moving forward, he will be involved in overseeing PreveCeutical’s development of therapeutic technologies, as well as managing the company’s ongoing operations in Australia, reviewing acquisition and licensing opportunities and leading commercialization efforts for its growing IP portfolio. “We are delighted to have Dr. Khaled as part of…

ThursdayFeb 22, 2018 1:34 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Sol-Gel Nose-to-Brain Delivery System of Cannabinoids

Universally-patient friendly, meaning formulations that can be used in children and adults alike Transport of drugs through blood-brain barrier marks top priority for researchers North American legal cannabis market projected at more than $24 billion by 2021 Global market for pain management, drugs and devices estimated at over $61 billion by 2023 PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is a Vancouver-based health sciences company dedicated to research and development of innovative, organic and Nature Identical™ options for preventive and curative therapies for a wide array of devastating medical conditions. Developing what the company believes will be the…

TuesdayFeb 13, 2018 3:56 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Aims to Halt Cancerous Tumor Progression Utilizing Scorpion Venom Product

Early-stage life sciences company PreveCeutical Medical’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) novel “scorpion venom” product builds on popular Cuban cancer-fighting therapy. An article discussing the company’s innovative solutions reads: “The scorpion venom product builds on discoveries in Cuba and the surrounding Caribbean nations advancing the popular belief that the venom inhibits the growth of cancer cells. PreveCeutical’s product, CELLB9Ò dietary supplement, utilizes select peptides from the blue scorpion (which is actually red, with a blue tail) to boost the user’s immune system, and the company is advancing its research into producing a “nature identical” scorpion peptide solution that it…

Site Search

Company Search

Tag: PreveCeutical Medical Inc. PRVCF